{
  "id": 10456546,
  "title": "MindRank Partners with 3SBio to Commercialize its AI-Designed Oral GLP-1 in China",
  "url": "https://urgent.news/2026/09/28/mindrank-partners-with-3sbio-to-commercialize-its-ai-designed-oral",
  "topic": "ai",
  "section": "AI",
  "published": "2026-09-28T13:35:39.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/mindrank-partners-with-3sbio-to-commercialize-its-ai-designed-oral-glp-1-in-china"
  },
  "original_language": "en",
  "account": null,
  "summary": "HANGZHOU, China, Sept. 28, 2026 (GLOBE NEWSWIRE) — MindRank AI Ltd. (“MindRank”) today announced that it has entered into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (“Mandi”) and Zhejiang Wansheng Pharmaceutical Co., Ltd. (“Wansheng”), both subsidiaries of 3SBio Inc. (01530.HK) group, for MDR-001, an AI-designed oral small-molecule GLP-1 receptor…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}